Bank of America Has Lowered Expectations for REGENXBIO (NASDAQ:RGNX) Stock Price

REGENXBIO (NASDAQ:RGNX) had its price target decreased by equities research analysts at Bank of America from $25.00 to $14.00 in a research report issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Bank of America‘s price objective suggests a potential upside of 139.93% from the stock’s current price.

Several other equities analysts have also recently issued reports on the stock. The Goldman Sachs Group reduced their price target on shares of REGENXBIO from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 10th. Robert W. Baird set a $27.00 price target on shares of REGENXBIO in a research report on Tuesday, February 10th. Barclays reduced their price target on shares of REGENXBIO from $37.00 to $12.00 and set an “overweight” rating on the stock in a research report on Friday. Wall Street Zen cut shares of REGENXBIO from a “hold” rating to a “sell” rating in a report on Saturday, January 31st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a report on Thursday, January 22nd. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, REGENXBIO has a consensus rating of “Moderate Buy” and a consensus price target of $23.91.

REGENXBIO Stock Performance

Shares of NASDAQ RGNX traded down $0.41 during midday trading on Friday, hitting $5.84. 2,810,619 shares of the company traded hands, compared to its average volume of 1,031,145. REGENXBIO has a 12-month low of $5.79 and a 12-month high of $16.19. The stock has a 50-day moving average price of $8.92 and a 200 day moving average price of $11.03. The firm has a market cap of $301.20 million, a P/E ratio of -1.55 and a beta of 1.12.

REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Thursday, May 14th. The biotechnology company reported ($1.72) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($1.82). REGENXBIO had a negative net margin of 113.75% and a negative return on equity of 103.12%. The company had revenue of $6.39 million for the quarter, compared to analysts’ expectations of $25.84 million. As a group, equities analysts expect that REGENXBIO will post -2.88 earnings per share for the current year.

Insiders Place Their Bets

In other REGENXBIO news, insider Steve Pakola sold 15,309 shares of the company’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $11.02, for a total value of $168,705.18. Following the sale, the insider owned 232,617 shares in the company, valued at approximately $2,563,439.34. This represents a 6.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 14.22% of the company’s stock.

Institutional Investors Weigh In On REGENXBIO

Institutional investors have recently made changes to their positions in the company. State of Alaska Department of Revenue purchased a new stake in shares of REGENXBIO during the third quarter valued at approximately $25,000. Aquatic Capital Management LLC purchased a new stake in shares of REGENXBIO during the third quarter valued at approximately $37,000. Jones Financial Companies Lllp grew its holdings in shares of REGENXBIO by 44.4% during the third quarter. Jones Financial Companies Lllp now owns 4,133 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 1,270 shares during the last quarter. Entropy Technologies LP purchased a new stake in shares of REGENXBIO during the first quarter valued at approximately $87,000. Finally, Captrust Financial Advisors purchased a new stake in shares of REGENXBIO during the second quarter valued at approximately $85,000. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Trending Headlines about REGENXBIO

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: REGENXBIO reported positive topline results from its pivotal AFFINITY DUCHENNE study of RGX-202, saying the primary endpoint was met with high statistical significance and that microdystrophin expression correlated with functional improvement, which supports the program’s development path and potential accelerated approval. Article Title
• Positive Sentiment: Management also highlighted additional pipeline catalysts, including progress for ABBV-RGX-314 in diabetic retinopathy, expected dosing in Q2, and other late-stage readouts later in 2026, which could create future upside if execution remains on track. Article Title
• Neutral Sentiment: The company’s earnings call and related coverage focused on the clinical update and broader pipeline strategy, with investors parsing whether the new trial data can translate into a commercial opportunity. Article Title
• Negative Sentiment: Q1 results were much worse than expected: REGENXBIO reported a larger-than-expected loss of $1.72 per share and revenue of $6.39 million versus consensus near $25.84 million, reinforcing concerns about the company’s financial runway and ongoing losses. Article Title
• Negative Sentiment: Market commentary also pointed to cash concerns and the scale of the quarterly loss as reasons the stock sold off, suggesting the encouraging Duchenne data was not enough to offset balance-sheet worries. Article Title
• Negative Sentiment: An insider sale by Steve Pakola added a small amount of negative sentiment, though this is less important than the trial and earnings news. Article Title

REGENXBIO Company Profile

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.